Zanubrutinib in Waldenström Macroglobulinemia-Reference-Cited by-同舟云学术

Zanubrutinib in Waldenström Macroglobulinemia

Published:2024-02-01 Issue:4 Volume:42 Page:481-482
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Song Yuan-bin¹^ORCID,Xu Jing-bo¹^ORCID,Gale Robert Peter¹^ORCID,Liang Yang¹^ORCID

Affiliation:

1. Yuan-bin Song, MD, Department of Hematologic Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation, Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China; Jing-bo Xu, MD, Department of Hematology, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong, China; Robert Peter Gale, MD, Department of Hematologic Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation, Center for Cancer Medicine,...

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.23.01881

Reference9 articles.

1. Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study

2. IBRUTINIB MONOTHERAPY PRODUCES LONG-TERM DISEASE CONTROL IN PREVIOUSLY TREATED WALDENSTROM'S MACROGLOBULINEMIA. FINAL REPORT OF THE PIVOTAL TRIAL (NCT01614821).

3. IBRUTINIB MONOTHERAPY PRODUCES LONG-TERM DISEASE CONTROL IN PREVIOUSLY TREATED WALDENSTROM'S MACROGLOBULINEMIA. FINAL REPORT OF THE PIVOTAL TRIAL (NCT01614821).

4. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

5. What is the (p-) value of the P-value?

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reply to Y. Song et al;Journal of Clinical Oncology;2024-02-01